TriangleEvorpacept (ALX148) (NCT07007559)
Evorpacept (ALX148) trial for Breast Cancer, Metastatic (NCT07007559). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic HER2-positive breast cancer after trastuzumab deruxtecan and progression on or after their latest treatment. No more than four prior HER2-directed treatment lines are allowed. A recent biopsy is required.
The idea: combine evorpacept and trastuzumab infusions every three weeks with one chemotherapy. Evorpacept blocks CD47, a signal that can protect cancer cells from immune clearance; trastuzumab targets HER2. Researchers measure tumor response and safety. The primary response analysis focuses on CD47-positive tumors.
This phase 2 study plans 120 patients. ALX Oncology sponsors twenty-eight recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.